Oncoheroes, member of CataloniaBio & HealthTech, announces that the US Food and Drug Administration (FDA) has allowed them to move forward with research on two of their potential paediatric oncology drugs, volasertib and dovitinib. This success reflects their unwavering commitment to pioneering therapies for children battling cancer.
"Receiving these announcements in the final days of Childhood Cancer Awareness Month has been an extraordinary gift," remarked Ricardo Garcia, Co-founder and CEO of Oncoheroes. "Our ongoing mission is to reshape the landscape of pediatric oncology, and these milestones accomplished stand as a testament to the dedication and determination of the entire Oncoheroes team."
In the coming months, they will continue to work tirelessly to advance the clinical trials of volasertib and dovitinib, with the goal of bringing these therapies one step closer to becoming a reality for paediatric cancer patients.
Comments